Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Advances in™ Targeted Therapies in AML and MDS: A Bullseye Approach to FLT3, IDH, and HMAs

Release Date: May 31, 2019
Expiration Date: May 31, 2020
Media: Internet - based

Activity Overview

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), comprise a spectrum of heterogeneous cancers, including progression from MDS to AML, and treatment. Many of the same difficulties are faced in treating both. Following decades of stagnation in AML therapy, 2017 and 2018 were watershed years, with active investigation into multiple drugs targeting FLT3, IDH1/2, CD33, CD123, Bcl-2, E-selectin, and epigenetic modifications. These agents offer new options for physicians and new hope and substantial benefits for patients with AML. The expanding arsenal of available therapies allows practitioners to further hone treatment and individualize care.

While novel therapies and combinations undeniably benefit patients with AML, they also add markedly to the complexity of the treatment decision-making process for a patient population with many medical comorbidities. It falls to the clinician to assess the clinical features of the patient along with the potential risks and benefits of each treatment option. This requires clinical experience as well as in-depth knowledge of practice guidelines, relevant clinical trial data, and methods to identify and mitigate the impact of treatment-related toxicities.

This educational program features video interviews with a top expert in AML who addresses the pathophysiology of AML, best practices for assessing genomic and karyotypic changes in AML to stratify patients, and the latest clinical data supporting the use of medications—those recently approved in AML as well as others in late-stage therapeutic development for AML and MDS.

Benefits of Participating

  • Increase knowledge and competence regarding evolving molecular targets and testing strategies in the management of patients with AML and MDS.
  • Improve competence in using novel targeted treatments to treat patients with AML and MDS, by understanding how to integrate these novel strategies into clinical practice.
  • Improve knowledge in identification and treatment of adverse events associated with novel targeted strategies.
  • Improve understanding of emerging evidence concerning the management and treatment of AML and MDS.

CME Activity Table of Contents

  • Module 1: Eye on the Target: How to Treat FLT3-Mutated AML
  • Module 2: Treating IDH1/2-Mutated AML: Incorporating IDH Into Clinical Practice
  • Module 3: Utilizing Hypomethylating Agents in AML
  • Module 4: The Future of Targeted Therapy in MDS and AML: A Pipeline Focus

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward oncologists, hematologists, nurse practitioners, physician assistants, fellows, nurses, and other healthcare professionals involved in the treatment and management of patients with AML and MDS.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Describe the biological characteristics of disease, testing strategies, and mechanisms of action for targeted agents in development for the treatment of AML
  • Determine how molecular markers are used to stratify risk and identify patient cohorts eligible for targeted agents approved and in development for AML
  • Apply current clinical trial evidence on targeted therapies in both frontline treatment and treatment of relapsed/refractory AML
  • Place emerging evidence on strategies to manage MDS into proper clinical context according to patients’ risk stratification

Faculty, Staff, and Planners’ Disclosures

Amir T. Fathi
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: Takeda, Celgene, Agios; Consultant: Takeda, Astellas, Agios, Celgene, Daiichi Sankyo, Jazz, Boston Biomedical.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By